While the initial focus for development was for the COVID-19 virus, it became obvious that the technology is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is “Without Limitation”.

Read More: https://investorshangout.com/post/view?id=581...z6R3NLWL8W